Clinical Trials Browser

Phase 2 × Cholangiocarcinoma × peginterferon alfa-2b × Clear all

NCT02982720 2022-02-16

Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

Phase 2 Terminated

4 enrolled 9 charts

Gastrointestinal

Cholangiocarcinoma